A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose
APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).